Methods for intracellular delivery of nucleic acids

Patent metadata

Field	Value
Publication number	US-9315829-B2
Application number	US-201113522839-A
Country	US
Kind code	B2
Filing date	Jan 14, 2011
Priority date	Jan 19, 2010
Publication date	Apr 19, 2016
Grant date	Apr 19, 2016

Abstract

A method for intracellular delivery of isolated naked nucleic acids into a biological tissue or organ, that includes (a) contacting the tissue or organ with an efficient amount of at least one active corticosteroid, and (b) contacting the tissue or organ treated in step b with an efficient amount of isolated naked nucleic acids, wherein step (a) is carried out for a period of time ranging from at least five minutes to at most two hours and being immediately followed by step (b).

First claim

The invention claimed is:

1. A method for intracellular delivery of at least one isolated naked nucleic acid into an ophthalmic tissue comprising a non-competent cell, said method comprising at least the steps of:
a/ contacting said ophthalmic tissue with an efficient amount of at least one active corticosteroid for a period of time ranging from at least five minutes to at most two hours; and, immediately following step a/,
b/ contacting said ophthalmic tissue treated in step a/ with an efficient amount of at least one isolated naked nucleic acid by injection into ciliary muscle;
wherein:
said at least one active corticosteroid is selected from the group consisting of triamcinolone, anecortave, derivatives thereof, and mixture thereof, and
said method does not include an electrotransfer step.

2. The method according to claim 1 , wherein said period of time of step a/ ranges from 10 to 90 minutes.

3. The method according to claim 1 , wherein said ophthalmic tissue is selected from the group consisting of ciliary muscle, retina tissue, Retinal Pigment Epithelium/choroid complex tissue, corneal endothelium, corneal epithelium, and glial retinal tissue.

4. The method according to claim 1 , wherein said isolated naked nucleic acid is selected from the group consisting of cDNA, gDNA, synthetic DNA, artificial DNA, recombinant DNA, mRNA, tRNA, siRNA, miRNA, shRNA, catalytic RNA, antisense RNA, viral RNA, peptidic nucleic acid, and mixtures thereof.

5. As method for promoting intracellular delivery of an isolated naked nucleic acid in an individual in need thereof, the method comprising:
administering to said individual a pharmaceutical composition comprising at least one corticosteroid as an active agent at least 5 minutes to at most 2 hours before administering to said individual said isolated naked nucleic acid, said isolated naked nucleic acid being administered by injection in a ciliary muscle in an ophthalmic tissue comprising a non-competent cell,
wherein;
said method does not include an electrotransfer step, and
said at least one active corticosteroid is selected from the group consisting of triamcinolone, anecortave, derivatives thereof, and mixture thereof.

6. A method for preventing and/or treating a disease selected from ocular proliferative diseases, ocular neurodegenerative diseases, ocular infectious diseases, ocular or intraocular inflammatory diseases, retinal degenerations, peripheral retinal degeneration, macular degeneration, ischemic and neovascular proliferative diseases, retinal vascular diseases, ocular ischemia syndrome and other vascular anomalies, macular oedema associated with age related macular degeneration, diabetic retinopathy, intraocular inflammation or retinal dystrophies, choroidal disorders and tumors, vitreous disorders, glial proliferation, angiogenesis, glaucoma, open angle glaucoma, neovascular glaucoma, macular pucker also called epiretinal membrane, retinal wrinkling, premacular fibrosis, and cellophane maculopathy, comprising the method of claim 5 .

Assignees

• Behar-Cohen Francine
• Touchard Elodie
• Univ Paris Descartes

Inventors

• Behar-Cohen Francine
• Touchard Elodie

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title

• A61K48/0083

  characterised by an aspect of the administration regime · CPC title